BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients
Reuters
Yesterday
BRIEF-<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients
Feb 19 (Reuters) - Traws Pharma Inc TRAW.O:
TRAWS PHARMA COMPLETES ANALYSIS OF RATUTRELVIR CLINICAL STUDY IN PAXLOVID®-ELIGIBLE AND INELIGIBLE COVID-19 PATIENTS AND PROVIDES UPDATES FOR ADDITIONAL INDICATION FOR TIVOXAVIR MARBOXIL AS A PROPHYLACTIC TREATMENT FOR SEASONAL INFLUENZA
TRAWS PHARMA INC - FDA PLACES CLINICAL HOLD ON TIVOXAVIR MARBOXIL IND
TRAWS PHARMA: FDA INTENDS TO COMMUNICATE ITS CONCERNS FORMALLY, TOGETHER WITH SUGGESTED MITIGATION STEPS, BY MARCH 16
TRAWS PHARMA INC: FDA INTENDS TO COMMUNICATE ITS CONCERNS FORMALLY, TOGETHER WITH SUGGESTED MITIGATION STEPS, BY MARCH 16
TRAWS PHARMA: FDA PLACED US IND FOR TIVOXAVIR MARBOXIL ON CLINICAL HOLD DUE TO CONCERNS WITH MUTAGENICITY DATA PACKAGE
Source text: ID:nGNXbypyCs
Further company coverage: TRAW.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.